OWP
PTGX icon

Obermeyer Wealth Partners’s Protagonist Therapeutics PTGX Stock Holding History

Obermeyer Wealth Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,242
Closed -$424K – 273
2024
Q2 		$424K Hold
12,242
– – 0.02% 160
2024
Q1 		$354K Buy
12,242
+176
+1% +$4.79K 0.02% 174
2023
Q4 		$277K Sell
12,066
-1,726
-13% -$30.2K 0.02% 183
2023
Q3 		$230K Buy
13,792
+1,180
+9% +$22.9K 0.02% 187
2023
Q2 		$348K Sell
12,612
-1,076
-8% -$26.9K 0.03% 147
2023
Q1 		$315K Sell
13,688
-662
-5% -$11.1K 0.02% 153
2022
Q4 		$157K Sell
14,350
-958
-6% -$8.08K 0.01% 218
2022
Q3 		$129K Buy
15,308
+34
+0.2% +$322 0.01% 206
2022
Q2 		$121K Sell
15,274
-786,351
-98% -$9.51M 0.01% 199
2022
Q1 		$19M Buy
801,625
+12,683
+2% +$357K 1.14% 29
2021
Q4 		$27M Buy
788,942
+12,253
+2% +$387K 1.45% 29
2021
Q3 		$13.8M Buy
776,689
+15,671
+2% +$668K 0.76% 36
2021
Q2 		$34.2M Buy
761,018
+374,946
+97% +$12.4M 1.9% 30
2021
Q1 		$10M Buy
+386,072
New +$9.77M 0.61% 39

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Obermeyer Wealth Partners's PTGX Position: Q3 2024 in Review

Obermeyer Wealth Partners sold out of Protagonist Therapeutics (PTGX) in Q3 2024, closing a stake of 12,242 shares — an estimated $424K sold.

Obermeyer Wealth Partners first reported a position in PTGX in Q1 2021 and held it in 14 quarters. The position peaked at $34.2M in Q2 2021. 240 funds tracked by Wall St. Rank hold PTGX as of Q3 2024.

  • Obermeyer Wealth Partners reported no remaining Protagonist Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Obermeyer Wealth Partners sold 12,242 Protagonist Therapeutics shares in Q3 2024, an estimated $424K.
  • Obermeyer Wealth Partners first reported a position in Protagonist Therapeutics in Q1 2021 and held it in 14 quarters.
  • Obermeyer Wealth Partners's Protagonist Therapeutics position peaked at $34.2M in Q2 2021.
  • 240 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2024.

Based on Obermeyer Wealth Partners's 13F filing for Q3 2024, filed 5 Nov 2024.